Ser28

Site Information
PKEVEEDsEDEEMsE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 452262

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , mutation of modification site ( 1 )
Disease tissue studied:	anthrax infection ( 12 ) , leukemia ( 8 ) , acute myelogenous leukemia ( 8 ) , melanoma skin cancer ( 18 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 4 ) , 'pancreatic, ductal'-pancreas ( 1 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 15 ) , 32Dcl3 (myeloid) ( 15 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 2 ) , blood ( 8 ) , brain ( 9 , 13 ) , heart ( 5 ) , Hepa 1-6 (epithelial) ( 19 ) , kidney ( 13 ) , liver ( 7 , 13 , 16 , 20 ) , lung ( 13 ) , macrophage-bone marrow ( 14 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 14 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 10 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 6 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 6 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 11 ) , MEF (fibroblast) ( 6 , 11 ) , pancreas ( 13 ) , RAW 264.7 (macrophage) ( 3 ) , RAW 267.4 (macrophage) ( 17 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 18 ) , spleen ( 12 , 13 ) , testis ( 13 )

Upstream Regulation
Regulatory protein:	KRas (human) ( 1 )
Putative in vivo kinases:	CK2A1 (human) ( 1 )
Treatments:	IFN-gamma ( 17 ) , insulin ( 4 ) , LY294002 ( 4 ) , silmitasertib ( 1 ) , Trametinib ( 1 )

Downstream Regulation
Effects of modification on NCL:	molecular association, regulation ( 1 )
Effects of modification on biological processes:	carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 ) , transcription, induced ( 1 )
Induce interaction with:	RNA ( 1 )

References
1	Azman MS, et al. (2023) An ERK1/2-driven RNA-binding switch in nucleolin drives ribosome biogenesis and pancreatic tumorigenesis downstream of RAS oncogene. EMBO J, e110902 37039106 Curated Info
2	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
3	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
4	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
5	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
6	Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3 23429704 Curated Info
7	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
8	Trost M, et al. (2012) Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood 120, e17-27 22802335 Curated Info
9	Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9 22807455 Curated Info
10	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
11	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
12	Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 21189417 Curated Info
13	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
14	Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371 20531401 Curated Info
15	Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39 19854140 Curated Info
16	Zhou J (2009) CST Curation Set: 7388; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
17	Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54 19144319 Curated Info
18	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
19	Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46 18846507 Curated Info
20	Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93 17242355 Curated Info